A lawyer for Tasmanian state government owned ports company TasPorts has criticised the ACCC’s first-of-its kind case that alleges it is misusing its market power to stymie competition, saying it isn’t clear what the regulator wants the court to do.
A leading class action and insolvency litigator at Squire Patton Boggs is leaving the firm to launch a boutique outfit with plans to shake up the legal industry, including by bringing class actions on a contingency fee basis.
ANZ has won access to documents the bank claims are crucial to its defence in a high stakes criminal cartel case, but the Australian Securities and Investments Commission has flagged a possible appeal of the ruling.
A former director of Atrum Coal has been ordered to pay over $6 million owed to a unit of Hong Kong finance giant Argonaut Group after a prior default saw the former executive lose $12 million worth of shares in the company.
A Gold Coast development property procured through a settlement with a Sydney-based financial advisory firm facing two separate class actions can be sold to recoup losses by investors who sank over $14 million into a property investment scheme, a court has found.
The NSW government has flagged a possible challenge to a class action over Sydney’s $3 billion delayed light rail project as the four-week trial scheduled for June is pushed back another year to allow time for more discovery.
Online real estate giant Domain has filed a lawsuit against an up-and-coming competitor in the property listings market, alleging the startup’s ads misleadingly claim it will have property listings before any of its rivals.
Three Sydney commercial landlords whose properties were compulsorily acquired to make way for the WestConnex project have come to the end of the road in their fight for $56.5 million in compensation, with the High Court refusing to hear their case.
ASIC has chalked up a victory in a long-running case against a Marshall Islands-based binary options trader, with a judge finding the trader engaged in the “deliberate deception of vulnerable people”.
Two biotech companies that provide molecular diagnostic products used in genetic screening will face off in Federal Court over whether one of the company’s ‘Access’ trade mark is likely to confuse consumers.